Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Operating Expenses (2023 - 2025)

Historic Other Operating Expenses for Spyre Therapeutics (SYRE) over the last 2 years, with Q2 2025 value amounting to $10.0 million.

  • Spyre Therapeutics' Other Operating Expenses changed N/A to $10.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 44347.83%. This contributed to the annual value of $16.4 million for FY2023, which is N/A changed from last year.
  • Spyre Therapeutics' Other Operating Expenses amounted to $10.0 million in Q2 2025.
  • Spyre Therapeutics' 5-year Other Operating Expenses high stood at $130.5 million for Q2 2023, and its period low was $1.8 million during Q4 2023.